A Phase 1 First-In-Human Study of the Anti-CD73 IPH5301 Alone or in Combination With Chemotherapy and Trastuzumab in Patients With Advanced Solid Tumors
Latest Information Update: 22 Mar 2024
At a glance
- Drugs IPH 5301 (Primary) ; Paclitaxel (Primary) ; Trastuzumab (Primary)
- Indications Advanced breast cancer; Carcinoma; Endometrial cancer; Gastric cancer; HER2 positive breast cancer; Lung cancer; Oesophageal cancer; Ovarian cancer; Pancreatic cancer
- Focus Adverse reactions; First in man
- Acronyms CHANCES
- 19 Mar 2024 Planned End Date changed from 1 Feb 2025 to 1 Feb 2026.
- 19 Mar 2024 Planned primary completion date changed from 1 Mar 2024 to 1 Mar 2025.
- 20 Apr 2023 Planned End Date changed from 1 Jul 2024 to 1 Feb 2025.